These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 25514466)

  • 1. The DHEA-sulfate depot following P450c17 inhibition supports the case for AKR1C3 inhibition in high risk localized and advanced castration resistant prostate cancer.
    Tamae D; Mostaghel E; Montgomery B; Nelson PS; Balk SP; Kantoff PW; Taplin ME; Penning TM
    Chem Biol Interact; 2015 Jun; 234():332-8. PubMed ID: 25514466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development, validation and application of a stable isotope dilution liquid chromatography electrospray ionization/selected reaction monitoring/mass spectrometry (SID-LC/ESI/SRM/MS) method for quantification of keto-androgens in human serum.
    Tamae D; Byrns M; Marck B; Mostaghel EA; Nelson PS; Lange P; Lin D; Taplin ME; Balk S; Ellis W; True L; Vessella R; Montgomery B; Blair IA; Penning TM
    J Steroid Biochem Mol Biol; 2013 Nov; 138():281-9. PubMed ID: 23851165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aldo-keto reductase family 1 member C3 (AKR1C3) is a biomarker and therapeutic target for castration-resistant prostate cancer.
    Hamid AR; Pfeiffer MJ; Verhaegh GW; Schaafsma E; Brandt A; Sweep FC; Sedelaar JP; Schalken JA
    Mol Med; 2013 Jan; 18(1):1449-55. PubMed ID: 23196782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dehydroepiandrosterone (DHEA)-SO
    Penning TM
    Vitam Horm; 2018; 108():309-331. PubMed ID: 30029732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of aldo-keto reductase 1C3 (AKR1C3) in LNCaP cells diverts androgen metabolism towards testosterone resulting in resistance to the 5α-reductase inhibitor finasteride.
    Byrns MC; Mindnich R; Duan L; Penning TM
    J Steroid Biochem Mol Biol; 2012 May; 130(1-2):7-15. PubMed ID: 22265960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer.
    Liu C; Lou W; Zhu Y; Yang JC; Nadiminty N; Gaikwad NW; Evans CP; Gao AC
    Cancer Res; 2015 Apr; 75(7):1413-22. PubMed ID: 25649766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of AKR1C3 Activation Overcomes Resistance to Abiraterone in Advanced Prostate Cancer.
    Liu C; Armstrong CM; Lou W; Lombard A; Evans CP; Gao AC
    Mol Cancer Ther; 2017 Jan; 16(1):35-44. PubMed ID: 27794047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 11β-Hydroxydihydrotestosterone and 11-ketodihydrotestosterone, novel C19 steroids with androgenic activity: a putative role in castration resistant prostate cancer?
    Storbeck KH; Bloem LM; Africander D; Schloms L; Swart P; Swart AC
    Mol Cell Endocrinol; 2013 Sep; 377(1-2):135-46. PubMed ID: 23856005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of (R)-2-(6-Methoxynaphthalen-2-yl)butanoic Acid as a Potent and Selective Aldo-keto Reductase 1C3 Inhibitor.
    Adeniji A; Uddin MJ; Zang T; Tamae D; Wangtrakuldee P; Marnett LJ; Penning TM
    J Med Chem; 2016 Aug; 59(16):7431-44. PubMed ID: 27486833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AKR1C3 Converts Castrate and Post-Abiraterone DHEA-S into Testosterone to Stimulate Growth of Prostate Cancer Cells via 5-Androstene-3β,17β-Diol.
    Detlefsen AJ; Mesaros CA; Duan L; Penning TM
    Cancer Res Commun; 2023 Sep; 3(9):1888-1898. PubMed ID: 37772993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 11-Oxygenated androgen precursors are the preferred substrates for aldo-keto reductase 1C3 (AKR1C3): Implications for castration resistant prostate cancer.
    Barnard M; Quanson JL; Mostaghel E; Pretorius E; Snoep JL; Storbeck KH
    J Steroid Biochem Mol Biol; 2018 Oct; 183():192-201. PubMed ID: 29936123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro CAPE inhibitory activity towards human AKR1C3 and the molecular basis.
    Li C; Zhao Y; Zheng X; Zhang H; Zhang L; Chen Y; Li Q; Hu X
    Chem Biol Interact; 2016 Jun; 253():60-5. PubMed ID: 27163852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ACSL3 promotes intratumoral steroidogenesis in prostate cancer cells.
    Migita T; Takayama KI; Urano T; Obinata D; Ikeda K; Soga T; Takahashi S; Inoue S
    Cancer Sci; 2017 Oct; 108(10):2011-2021. PubMed ID: 28771887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ERG/AKR1C3/AR Constitutes a Feed-Forward Loop for AR Signaling in Prostate Cancer Cells.
    Powell K; Semaan L; Conley-LaComb MK; Asangani I; Wu YM; Ginsburg KB; Williams J; Squire JA; Maddipati KR; Cher ML; Chinni SR
    Clin Cancer Res; 2015 Jun; 21(11):2569-79. PubMed ID: 25754347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of potent and selective indomethacin analogues for the inhibition of AKR1C3 (Type 5 17β-hydroxysteroid dehydrogenase/prostaglandin F synthase) in castrate-resistant prostate cancer.
    Liedtke AJ; Adeniji AO; Chen M; Byrns MC; Jin Y; Christianson DW; Marnett LJ; Penning TM
    J Med Chem; 2013 Mar; 56(6):2429-46. PubMed ID: 23432095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of potent and selective inhibitors of aldo-keto reductase 1C3 (type 5 17β-hydroxysteroid dehydrogenase) based on N-phenyl-aminobenzoates and their structure-activity relationships.
    Adeniji AO; Twenter BM; Byrns MC; Jin Y; Chen M; Winkler JD; Penning TM
    J Med Chem; 2012 Mar; 55(5):2311-23. PubMed ID: 22263837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer.
    Hofland J; van Weerden WM; Dits NF; Steenbergen J; van Leenders GJ; Jenster G; Schröder FH; de Jong FH
    Cancer Res; 2010 Feb; 70(3):1256-64. PubMed ID: 20086173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of 2-methyl-1-{1-[(5-methyl-1H-indol-2-yl)carbonyl]piperidin-4-yl}propan-2-ol: a novel, potent and selective type 5 17β-hydroxysteroid dehydrogenase inhibitor.
    Watanabe K; Kakefuda A; Yasuda M; Enjo K; Kikuchi A; Furutani T; Naritomi Y; Otsuka Y; Okada M; Ohta M
    Bioorg Med Chem; 2013 Sep; 21(17):5261-70. PubMed ID: 23845281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hydroxytriazole derivatives as potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors discovered by bioisosteric scaffold hopping approach.
    Pippione AC; Giraudo A; Bonanni D; Carnovale IM; Marini E; Cena C; Costale A; Zonari D; Pors K; Sadiq M; Boschi D; Oliaro-Bosso S; Lolli ML
    Eur J Med Chem; 2017 Oct; 139():936-946. PubMed ID: 28881288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An indomethacin analogue, N-(4-chlorobenzoyl)-melatonin, is a selective inhibitor of aldo-keto reductase 1C3 (type 2 3alpha-HSD, type 5 17beta-HSD, and prostaglandin F synthase), a potential target for the treatment of hormone dependent and hormone independent malignancies.
    Byrns MC; Steckelbroeck S; Penning TM
    Biochem Pharmacol; 2008 Jan; 75(2):484-93. PubMed ID: 17950253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.